A prospective multi-institutional observational study to explore novel biomarkers of chemo-radiation therapy combined with durvalumab to patients with unresectable stage III non-small cell lung cancer (WJOG11518L)
Not Applicable
- Conditions
- ocally advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000035916
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 143
Inclusion Criteria
Not provided
Exclusion Criteria
1) previous treatment with PD-1 or PD-L1 inhibitor treatment 2) postoperative recurrence of non-small cell lung cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association of biomarkers with progression-free survival
- Secondary Outcome Measures
Name Time Method Association of biomarkers with overall survival, association of biomarkers with immune-related adverse event, association of biomarkers with response rate, association of biomarkers with disease control rate, cut-off values of biomarkers, association of biomarkers with immune-related gene expression, association among biomarkers